For example, in a patient with BRAF V600E, osimertinib-resistant NSCLC, serious toxicity led to a dose reduction of dabrafenib plus trametinib in combination with the ordinary dose of osimertinib [59]. Here, BRAF is linked to non-small cell lung carcinoma.